ArticleMicromachines2022
A Magnetorheological Duckbill Valve Micropump for Drug Delivery Applications.
Article in Micromachines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In this study, we propose a duckbill valve microfluidic pump that relies on an electromagnetic actuation mechanism. An FEA/CFD-based approach was adopted for the design of the device due to the coupled electromagnetic-solid-fluid interactions in the device. The simulation methodology was confirmed with the previously published data in the literature to ensure the accuracy of the simulations. The proposed optimum duckbill valve micropump can pump 2.45 µL of fluid during the first 1 s, including both contraction and expansion phases, almost 16.67% more than the basic model. In addition, the model can pump a maximum volume of 0.26 µL of fluid at the end of the contraction phase (at 0.5 s) when the magnetic flux density is at maximum (0.027 T). The use of a duckbill valve in the model also reduces the backflow by almost 7.5 times more than the model without any valve. The proposed device could potentially be used in a broad range of applications, such as an insulin dosing system for Type 1 diabetic patients, artificial organs to transport blood, organ-on-chip applications, and so on.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.